Security
JAZZ · Jazz Pharmaceuticals plc
JAZZNASDAQCommon stockCurrentCIK 1232524Updated Sep 26, 2026
Name history
JAZZ PHARMACEUTICALS INC · through Jan 18, 2012
JAZZ price & chart
Loading TradingView…
NASDAQ:JAZZ on TradingView ↗About the company
global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease - often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.
In the news
Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance USA - English USA - English News provided by Jazz Pharmaceuticals plc Nov 05, 2025, 16:05 ET Share this article Share to X Share this article Share to X – Modeyso™ approved as the first and only t ↗
Recent filings
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 1.01, 2.03, 9.01
Regulation FD Disclosure
Items 7.01
4 filing
144 filing
144 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 11,659,340,000Source | 12,012,257,000Source | 11,393,359,000Source | 10,835,255,000Source |
| GoodwillUSD | 1,829,340,000Source | 1,716,323,000Source | 1,753,130,000Source | 1,692,662,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 4,429,510,000Source | 4,755,695,000Source | 5,418,039,000Source | 5,794,437,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 1,391,899,000Source | 2,412,864,000Source | 1,506,310,000Source | 881,482,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 830,747,000Source | 716,765,000Source | 705,794,000Source | 651,493,000Source |
| Inventory, NetUSD | 416,962,000Source | 480,445,000Source | 597,039,000Source | 714,061,000Source |
| Assets, CurrentUSD | 4,166,043,000Source | 4,629,028,000Source | 3,435,428,000Source | 2,606,140,000Source |
| Operating Lease, Right-of-Use AssetUSD | 58,880,000Source | 53,582,000Source | 65,340,000Source | 73,326,000Source |
| Other Assets, NoncurrentUSD | 99,030,000Source | 114,482,000Source | 67,464,000Source | 55,139,000Source |
| LIABILITIES AND EQUITY | ||||
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 6,000Source | 6,000Source | 6,000Source | 6,000Source |
| Retained Earnings (Accumulated Deficit)USD | 646,176,000Source | 1,127,347,000Source | 878,656,000Source | 733,586,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -568,598,000Source | -947,667,000Source | -842,147,000Source | -1,125,509,000Source |
| Stockholders' Equity Attributable to ParentUSD | 4,318,584,000Source | 4,093,756,000Source | 3,736,997,000Source | 3,085,734,000Source |
| Additional Paid in Capital, Common StockUSD | 4,240,472,000Source | 3,913,542,000Source | 3,699,954,000Source | 3,477,124,000Source |
| Liabilities and EquityUSD | 11,659,340,000Source | 12,012,257,000Source | 11,393,359,000Source | 10,835,255,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 2,242,521,000Source | 1,038,573,000Source | 1,536,692,000Source | 933,193,000Source |
| Operating Lease, Liability, CurrentUSD | 14,278,000Source | 14,331,000Source | 19,019,000Source | 15,557,000Source |
| Accounts Payable, CurrentUSD | 122,061,000Source | 77,869,000Source | 102,750,000Source | 90,758,000Source |
| Operating Lease, Liability, NoncurrentUSD | 50,892,000Source | 38,938,000Source | 59,225,000Source | 71,838,000Source |
| Deferred Income Tax Liabilities, NetUSD | 594,470,000Source | 676,736,000Source | 847,706,000Source | 944,337,000Source |
| Other Liabilities, NoncurrentUSD | 124,519,000Source | 86,614,000Source | 104,751,000Source | 106,812,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 1,034,170,000Source | 910,947,000Source | 793,914,000Source | 803,255,000Source |
| Deferred Tax Liabilities, NetUSD | — | 116,491,000Source | 369,872,000Source | 568,090,000Source |
| Long-term Debt, Excluding Current Maturities | — | — | — | — |
| Long-term Debt, Current MaturitiesUSD | 1,029,903,000Source | 31,000,000Source | 604,954,000Source | 31,000,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 4,328,354,000Source | 6,077,640,000Source | 5,107,988,000Source | 5,693,341,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 41,600,000Source | 32,800,000Source | 30,400,000Source | 30,300,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 291,133,000Source | 248,045,000Source | 226,841,000Source | 221,996,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 106,279,000Source | 21,115,000Source | 51,883,000Source | 90,135,000Source |
| Increase (Decrease) in InventoriesUSD | 86,041,000Source | 45,542,000Source | 13,420,000Source | 49,642,000Source |
| Increase (Decrease) in Accounts PayableUSD | 39,851,000Source | -20,073,000Source | 9,603,000Source | -11,225,000Source |
| Deferred Income Tax Expense (Benefit)USD | -444,971,000Source | -208,327,000Source | -260,217,000Source | -292,251,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 1,355,773,000Source | 1,395,908,000Source | 1,092,007,000Source | 1,271,977,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | 0Source | 0Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -1,509,913,000Source | -508,195,000Source | -163,062,000Source | -446,230,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 58,752,000Source | 38,070,000Source | 23,962,000Source | 29,046,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 75,220,000Source | 57,753,000Source | 50,952,000Source | 45,443,000Source |
| Payments for Repurchase of Common StockUSD | 125,023,000Source | 311,429,000Source | 269,761,000Source | 54,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -873,380,000Source | 20,516,000Source | -305,254,000Source | -529,491,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -1,020,965,000Source | 906,554,000Source | 624,828,000Source | 290,034,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 1,391,899,000Source | 2,412,864,000Source | 1,506,310,000Source | 881,482,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 248,553,000Source | 314,822,000Source | 333,112,000Source | 270,671,000Source |
| Income Taxes Paid, NetUSD | 121,808,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 6,555,000Source | -1,675,000Source | 1,137,000Source | -6,222,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 291,133,000Source | 248,045,000Source | 226,841,000Source | 221,996,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | 4,200,000Source | — |
| Amortization of Intangible AssetsUSD | 654,661,000Source | 627,313,000Source | 608,284,000Source | 599,169,000Source |
| Deferred Other Tax Expense (Benefit)USD | -13,582,000Source | -11,481,000Source | -8,990,000Source | -11,144,000Source |
| DepreciationUSD | 41,636,000Source | 32,754,000Source | 30,412,000Source | 30,302,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -2,568,000Source | -8,182,000Source | 8,787,000Source | -19,014,000Source |
| Gain (Loss) on Disposition of BusinessUSD | — | 0Source | 0Source | -37,704,000Source |
| GoodwillUSD | 1,829,340,000Source | 1,716,323,000Source | 1,753,130,000Source | 1,692,662,000Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | 0Source | 0Source | — |
| Income (Loss) from Equity Method InvestmentsUSD | -732,000Source | -1,660,000Source | -3,009,000Source | -9,921,000Source |
| Income Tax Expense (Benefit)USD | -272,443,000Source | -91,429,000Source | -119,912,000Source | -158,645,000Source |
| Investment Income, InterestUSD | 85,800,000Source | 106,300,000Source | 65,100,000Source | 11,500,000Source |
| Net Income (Loss) Attributable to ParentUSD | -356,148,000Source | 560,120,000Source | 414,832,000Source | -224,060,000Source |
| Payments to Acquire InvestmentsUSD | 1,830,275,000Source | 1,305,125,000Source | 390,100,000Source | 61,036,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 4,267,586,000Source | 4,068,950,000Source | 3,834,204,000Source | 3,659,374,000Source |
| Selling, General and Administrative ExpenseUSD | 1,809,271,000Source | 1,385,294,000Source | 1,343,105,000Source | 1,416,967,000Source |
| Operating Income (Loss)USD | -430,240,000Source | 716,630,000Source | 578,580,000Source | -65,528,000Source |
| Income Tax Expense (Benefit)USD | -272,443,000Source | -91,429,000Source | -119,912,000Source | -158,645,000Source |
| Net Income (Loss) Attributable to ParentUSD | -356,148,000Source | 560,120,000Source | 414,832,000Source | -224,060,000Source |
| Earnings Per Share, BasicUSD per share | -5.84Source | 9.06Source | 6.55Source | -3.58Source |
| Earnings Per Share, DilutedUSD per share | -5.84Source | 8.65Source | 6.1Source | -3.58Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 60,981,000Source | 61,838,000Source | 63,291,000Source | 62,539,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 60,981,000Source | 66,007,000Source | 72,066,000Source | 62,539,000Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 654,661,000Source | 627,313,000Source | 608,284,000Source | 599,169,000Source |
| Costs and ExpensesUSD | 4,697,826,000Source | 3,352,320,000Source | 3,255,624,000Source | 3,724,902,000Source |
| Current Income Tax Expense (Benefit)USD | 172,528,000Source | 116,898,000Source | 140,305,000Source | 133,606,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -2,568,000Source | -8,182,000Source | 8,787,000Source | -19,014,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 164,697,000Source | 497,860,000Source | 449,214,000Source | -50,311,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | -732,000Source | -1,660,000Source | -3,009,000Source | -9,921,000Source |
| Interest Expense, DebtUSD | — | — | 32,800,000Source | 32,800,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | -195,051,000Source | -238,097,000Source | -289,438,000Source | -288,242,000Source |
| Investment Income, InterestUSD | 85,800,000Source | 106,300,000Source | 65,100,000Source | 11,500,000Source |
Filing attachments
d106596dex991.htm · 8-K · 2026-08-10
EX-99.1 2 d106596dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 FINAL Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio Adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1+ epilepsy Leverages Jazz development expertise and commercial strength in rare and severe epilepsies Transaction includes $820 million upfront payment DUBLIN and SAN DIEGO, August 10, 2026 - Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Actio Biosciences,…
Read attachment ↗d61589dex991.htm · 8-K · 2026-01-12
EX-99.1 2 d61589dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 January 2026 44th Annual J.P. Morgan Healthcare Conference Redefining Possibilities in Rare Disease Renee Gala, President & CEO Transforming Lives. Redefining Possibilities. Caution Concerning Forward-Looking Statements This presentation contains forward-looking statements and financial targets, including, but not limited to, statements related to: the Company’s growth prospects and future financial and operating results, including t…
Read attachment ↗d827060dex991.htm · 8-K · 2025-11-17
EX-99.1 2 d827060dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma Ziihera plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful effect w…
Read attachment ↗d15137dex991.htm · 8-K · 2025-07-10
EX-99.1 2 d15137dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer -Selection Follows Robust Succession Process Led by the Board- -Bruce Cozadd to Retire as CEO and Remain Chairperson of the Board of Directors- DUBLIN, July 10, 2025 - Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Jazz Board of Directors has unanimously selected Renee Gala, Jazz’s President and Chief Operating Officer, as the President…
Read attachment ↗d887871dex991.htm · 8-K · 2025-04-21
EX-99.1 2 d887871dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Jazz Pharmaceuticals Completes Acquisition of Chimerix -Addition of dordaviprone strengthens Jazz’s late-stage oncology pipeline and reinforces commitment to addressing rare diseases with significant unmet need- DUBLIN, April 21, 2025 - Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) today announced the successful completion of its acquisition of Chimerix, Inc. (“Chimerix”) for approximately $935 million in cash.…
Read attachment ↗d927269dex991.htm · 8-K · 2025-03-05
EX-99.1 3 d927269dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio -Dordaviprone addresses a significant unmet patient need for patients with rare, high-grade brain tumors- -Transaction to add near-term commercial opportunity to Jazz’s pipeline- -Transaction represents total cash consideration of approximately $935 million, or $8.55 per share- DUBLIN and DURHAM, March 5, 2025 - Jazz Pharmaceuticals plc (Nasdaq: JAZ…
Read attachment ↗